Manuscript no. HAEMATOL/2010/038976 entitled “Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia”


Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
• Marry M. Van den Heuvel-Eibrink, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children’s Hospital, Rotterdam, The Netherlands; m.vandenheuvel@erasmusmc.nl
• C. Michel Zwaan, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children’s Hospital, Rotterdam, The Netherlands; c.m.zwaan@erasmusmc.nl
• Rob Pieters, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children’s Hospital, Rotterdam, The Netherlands; rob.pieters@erasmusmc.nl
• Brian V. Balgobind, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children’s Hospital, Rotterdam, The Netherlands; b.balgobind@erasmusmc.nl
• Iris H.I.M. Hollink, Pediatric Oncology/Hematology, Erasmus MC - Sophia Children’s Hospital, Rotterdam, The Netherlands; i.hollink@erasmusmc.nl

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Marry M. Van den Heuvel-Eibrink, C. Michel Zwaan, Rob Pieters, Brian V. Balgobind and Iris H.I.M. Hollink

3) Design & Methods. The following authors were responsible for specific investigations:
• Brian V. Balgobind, Iris H.I.M. Hollink, Susan T.J.C.M. Arentsen-Peters, Jacqueline Cloos, were responsible for mutation analysis
• Martin Zimmermann, Brian V. Balgobind and Iris H.I.M. Hollink were responsible for statistical analysis.
• Valerie de Haas, Gert-Jan J.L. Kaspers, Dirk Reinhardt, Jean-Michel Cayuela, Andre Baruchel and Jan Stary were responsible for providing patient samples and patients’characteristics of study group patients.
• H. Berna Beverloo, Anne R.M. von Bergh, Jochen Harbott and Zuzana Zemanova were responsible for cytogenetic analysis of the samples.

4) Results. The following authors were responsible for specific portions of the results, including figures and tables:
• Brian V. Balgobind and Iris H.I.M Hollink were responsible for all results, figures and tables.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
• Brian V. Balgobind, Iris H.I.M Hollink, Marry M. Van den Heuvel-Eibrink, C. Michel Zwaan, Rob Pieters were responsible for writing the manuscript.

6) Contributors Listed in Acknowledgments:
B.V.B was funded by the 'Netherlands Organisation for Scientific Research' (NWO) and the KOCR foundation. I.H.I.M.H. was funded by the KOCR foundation. H.B.B. was partly funded by the Dutch Cancer Society (grant EMCR 2003-2871).